Details of the Drug Reposition

General Information of This Drug (ID: DM5D6Y7)

Drug Name
OBI-3424   DM5D6Y7
Synonyms
UNII-X6SH5T8H76; X6SH5T8H76; CHEMBL4297474; SCHEMBL20870529; 2097713-68-1; 3-(5-((1R)-1-(Bis(aziridin-1-yl(phosphoryloxy)ethyl)-2-nitrophenoxy)-N,N-dimethylbenzamide; Phosphinic acid, P,P-bis(1-aziridinyl)-, (1R)-1-(3-(3-((dimethylamino)carbonyl)phenoxy)-4-nitrophenyl)ethyl ester
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute lymphoblastic leukaemia DIS87TGM 2A85 Phase 2 [1]
------------------------------------------------------------------------------------
3 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1/2 [2]
Hepatocellular carcinoma DIS0J828 2C12.02 Phase 1/2 [2]
Prostate cancer DISF190Y 2C82.0 Phase 1/2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04315324) Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT03592264) This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer. U.S. National Institutes of Health.